scholarly journals Predicting Therapeutic Efficacy of Vascular Disrupting Agent CA4P in Rats with Liver Tumors by Hepatobiliary Contrast Agent Mn-DPDP-Enhanced MRI

2020 ◽  
Vol 13 (1) ◽  
pp. 92-101 ◽  
Author(s):  
Yewei Liu ◽  
Qiu Guan ◽  
Xiangyong Kong ◽  
Frederik De Keyzer ◽  
Yuanbo Feng ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Therapeutic Efficacy ◽  
Liver Tumors ◽  
Vascular Disrupting Agent ◽  
Enhanced Mri ◽  
Vascular Disrupting

Contrast-Enhanced MRI of Focal Liver Tumors Using a Hepatobiliary MR Contrast Agent

2002 ◽  
Vol 9 (1) ◽  
pp. S119-S120 ◽  
Author(s):  
Renate Hammerstingl ◽  
Stephan Zangos ◽  
Wolfram Schwarz ◽  
Thomas Rosen ◽  
Wolf-Otto Bechstein ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Liver Tumors ◽  
Enhanced Mri ◽  
Contrast Enhanced ◽  
Contrast Enhanced Mri

scholarly journals TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

2011 ◽  
Vol 121 (5) ◽  
pp. 1969-1973 ◽  
Author(s):  
Abigail F. Welford ◽  
Daniela Biziato ◽  
Seth B. Coffelt ◽  
Silvia Nucera ◽  
Matthew Fisher ◽  
...  
Keyword(s):  
Therapeutic Efficacy ◽  
Vascular Disrupting Agent ◽  
Combretastatin A4 ◽  
Vascular Disrupting

scholarly journals Evaluation of non-targeting, C- or N-pH (low) insertion peptide modified superparamagnetic iron oxide nanoclusters for selective MRI of liver tumors and their potential toxicity in cirrhosis

RSC Advances ◽  
2019 ◽  
Vol 9 (25) ◽  
pp. 14051-14059
Author(s):  
Abdulrahman Ahmed Mahmood ◽  
Jianqi Zhang ◽  
Rufang Liao ◽  
Xiwei Pan ◽  
Dan Xu ◽  
...  
Keyword(s):  
Iron Oxide ◽  
Liver Cancer ◽  
Contrast Agent ◽  
Cancer Diagnosis ◽  
Liver Tumors ◽  
Superparamagnetic Iron Oxide ◽  
Mri Contrast Agent ◽  
Potential Toxicity ◽  
Mri Contrast ◽  
Specific Enhancement

The acid-responsive pHLIP modified SPION as an MRI contrast agent for liver cancer diagnosis requires the validation of both the tumor-specific enhancement and a safe profile in cirrhosis.

The Novel Vascular Disrupting Agent ANG501 Induces Cell Cycle Arrest and Enhances Endothelial Cell Sensitivity to Radiation

2009 ◽  
Vol 2 ◽  
pp. CGM.S2596 ◽  
Author(s):  
Shona T. Dougherty ◽  
Sean E. Walker ◽  
Peter D. Davis ◽  
Graeme J. Dougherty
Keyword(s):  
Cell Cycle ◽  
Endothelial Cells ◽  
Normal Cell ◽  
Cell Cycle Progression ◽  
Stress Proteins ◽  
Vascular Disrupting Agent ◽  
Heat Shock Stress ◽  
Cell Cycling ◽  
Vascular Disrupting

The efficacy of approaches in which vascular disrupting agents (VDA) are used in combination with conventional chemotherapy and/or radiation therapy in the treatment of cancer might be improved if there were a better understanding of the cellular and molecular changes induced in normal and malignant cells as a result of VD A exposure. Toward this goal, murine endothelial cells were treated in vitro with ANG501, a novel stilbene VDA developed in our laboratory, and alterations in gene expression determined by genome-wide microarray analysis and subsequently confirmed by Western blot analysis. Among the genes that were shown to be induced upon brief exposure to non-cytotoxic doses of ANG501 were several involved in the control of cell cycle progression and apoptosis, including p21Wafl and the heat shock/stress proteins hsp25, hsp70 and anti-B-crystallin. Reflecting such induction, functional studies confirmed that normal cell cycling is temporarily inhibited following treatment with ANG501 such that the majority of cells accumulate at the radiation-sensitive G2/M phase of the cell cycle at 6 hr. The effects were transient and by 24 hr normal cell cycling had largely resumed. Combination experiments confirmed that endothelial cells treated 6 hr previously with ANG501 were more readily killed by radiation. Importantly, significant effects were evident at clinically relevant radiation doses. Taken together these findings emphasize the need to consider the radiosensitizing activity of VD As when developing therapies in which these promising compounds are used in combination with radiation.

Combretastatin A4 phosphate: a novel vascular disrupting agent

2010 ◽  
Vol 6 (8) ◽  
pp. 1219-1228 ◽  
Author(s):  
Govardhanan Nagaiah ◽  
Scot C Remick
Keyword(s):  
Vascular Disrupting Agent ◽  
Combretastatin A4 ◽  
Vascular Disrupting

scholarly journals Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent

2010 ◽  
Vol 103 (5) ◽  
pp. 597-606 ◽  
Author(s):  
J D Lickliter ◽  
A B Francesconi ◽  
G Smith ◽  
M Burge ◽  
A Coulthard ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Trial ◽  
Vascular Disrupting Agent ◽  
Vascular Disrupting
Sign in / Sign up

Export Citation Format

Share Document